Research resource only — not medical advice. Compounds covered include FDA-approved prescription medications and investigational peptides. All applications require physician evaluation. Dr. Scott DelBoccio, DMD, author.
Research Hub · PeptideReport.ai · Physician-Authored
The peptide pharmacology of sexual function operates through two distinct central axes: the melanocortin system (MC3R/MC4R), which regulates desire and arousal via hypothalamic circuits, and the kisspeptin/GnRH axis, which governs reproductive hormone pulsatility. One compound — PT-141 (Vyleesi®) — has achieved FDA approval in this space, making it the highest-evidence peptide in the Sexual Health library and the only FDA-approved CNS-acting pro-sexual medication for women.
Compounds Profiled
4
FDA-Approved
1 — PT-141
Primary Axes
Melanocortin · Kisspeptin
Evidence Range
Level I → Level V
Hub Author
Dr. Scott DelBoccio, DMD
Central Mechanisms
Two Hypothalamic Axes That Govern Sexual Function
Sexual desire and arousal are centrally organized processes — the relevant pharmacology is not peripheral. The melanocortin system and the kisspeptin/GnRH system represent the two most pharmacologically tractable axes in this space, and the compounds in this library act on one or both. Understanding which axis a compound targets — and what that means for its clinical role — is the foundation for evidence-based selection.
Melanocortin Axis — Arousal & Desire
Origin: Hypothalamic proopiomelanocortin (POMC) neurons; cleave to produce α-MSH and other melanocortin peptides
Endogenous function: α-MSH → MC4R in PVN → oxytocin release → downstream arousal signaling; also modulates dopaminergic reward circuits via limbic MC3R
Pharmacological access: PT-141 (bremelanotide) — MC3R/MC4R agonist; selective enough for CNS effects without major peripheral melanocortin (pigmentation/MSH) side effects at therapeutic doses
Clinical application: Hypoactive Sexual Desire Disorder (HSDD); Female Sexual Interest/Arousal Disorder (FSIAD); erectile dysfunction (off-label)
Kisspeptin/GnRH Axis — Reproductive Pulsatility
Origin: Kisspeptin-1 neurons in the arcuate and anteroventral periventricular nuclei; the master regulator of GnRH secretion
Endogenous function: Gate-keeper of puberty onset; regulates GnRH pulsatility throughout reproductive life; kisspeptin deficiency = hypothalamic amenorrhea and infertility; integrates metabolic signals (leptin, insulin) with reproductive axis output
Pharmacological access: Kisspeptin-10 and kisspeptin-54 (research peptides); no FDA-approved KISS1R agonist exists yet; Phase II trials in IVF/anovulation
PT-141 (Vyleesi®)→MC3R + MC4R agonism→FDA-approved: HSDD in premenopausal women (2019)
The melanocortin axis is the only currently FDA-approved pharmacological target for female sexual desire. PT-141's approval validates MC4R agonism as a biologically real therapeutic mechanism — not a placebo-mediated outcome. This distinguishes the melanocortin approach from prior FDA rejections of pharmaceutical HSDD therapies (flibanserin's mechanism was 5-HT/dopaminergic and received a narrower approval).
Pharmacology Deep-Dive
Melanocortin Receptor Subtype Map — Why Selectivity Is Everything
Five melanocortin receptor subtypes exist (MC1R through MC5R), each with distinct tissue distribution and physiological roles. The critical clinical insight: the desired sexual effects of melanocortin agonism come specifically from MC3R (limbic desire) and MC4R (PVN arousal/erectile). Agonism of other receptor subtypes — particularly MC1R (tanning) and MC5R (exocrine glands) — produces the unwanted side effects that defined early melanocortin compound development. PT-141's approval is built on this selectivity insight.
Receptor
Primary Location
Physiological Role
PT-141 (Vyleesi®) Activation
Melanotan II Activation
MC1R
Melanocytes, skin, hair follicles
Eumelanin production (tanning); hair pigmentation; UV-protective melanogenesis; implicated in melanoma risk regulation
Minimal — PT-141's cyclic structure confers reduced MC1R affinity; tanning is not a clinical effect at therapeutic doses
Strong agonist — tanning, hyperpigmentation, and nevi enlargement are expected clinical effects; melanoma risk concern
Primary sexual arousal and erectile function receptor; PVN MC4R → oxytocin release → penile/clitoral tumescence; also regulates energy homeostasis and food intake
Primary therapeutic target — MC4R agonism in the PVN is the pharmacological basis of PT-141's FDA approval; oxytocin-mediated arousal downstream
Activated non-selectively; same MC4R effects but with concurrent MC1R/MC5R activation producing more off-target adverse effects
Regulates exocrine gland secretion; sebum production; tears and salivary output; implicated in skin barrier function
Minimal clinically relevant activation at therapeutic PT-141 doses
Activated — contributes to flushing, sebaceous gland effects, and skin-related adverse effects of Melanotan II
The Clinical Bottom Line on MC Selectivity
PT-141 is not simply a "safer Melanotan II" — it is a structurally engineered compound that achieves the MC3R/MC4R-mediated clinical effects while minimizing MC1R and MC5R activation. The cyclic peptide modification (vs. MT-II's linear structure) drives this selectivity. The practical consequence: at the FDA-approved 1.75 mg SC dose, PT-141 produces desire and arousal effects without tanning, without nevi enlargement risk, and with a substantially more manageable side effect profile. Nausea (the dose-limiting side effect) is a Class effect of MC receptor activation on area postrema MC4R — not a selectivity failure, but a manageable on-mechanism adverse effect.
Standard of Care — Pre-Treatment Workup
Hormonal Optimization Must Precede Peptide Consideration
The most common clinical error in sexual health peptide prescribing is bypassing the hormonal workup. PT-141's Phase III data — and its FDA approval — was generated in patients with normal endogenous hormone levels. The melanocortin system modulates desire at the CNS level, but a substrate of adequate sex hormone levels is required for the melanocortin circuit to respond. Testosterone and estrogen deficiency must be identified and addressed before attributing low desire to a central melanocortin deficit.
Standard Workup Before Sexual Health Peptide Consideration
In women: FSH/LH, estradiol, total and free testosterone, SHBG, TSH, prolactin, CBC, CMP. In men: total and free testosterone, LH, FSH, estradiol, prolactin, SHBG, TSH, CBC, CMP. Correct deficiencies first — a woman with low free testosterone from high SHBG should receive SHBG optimization and testosterone therapy before PT-141 is added. PT-141 is an adjunct to, not a replacement for, hormonal optimization.
Lab Finding
Clinical Significance in Sexual Health Context
First-Line Intervention
Role of Peptide After Optimization
Low Free Testosterone (women)
Primary driver of low desire in most premenopausal and postmenopausal women; most common correctable hormonal cause of HSDD; often masked by high SHBG
PT-141 may be added as an on-demand adjunct after testosterone optimization if residual desire deficit persists; not indicated as a substitute for testosterone therapy
Low Estradiol (women)
Drives vulvovaginal atrophy (pain with sex) and may contribute to central desire suppression; menopausal estrogen deficiency affects MC-receptor sensitivity indirectly
Systemic or local estrogen therapy (transdermal preferred for GH-axis interactions; no relevant interaction with PT-141)
Address estrogen first — many desire complaints resolve with adequate estradiol. PT-141 addresses central desire; local estrogen addresses arousal and comfort separately
Elevated Prolactin
Hyperprolactinemia suppresses GnRH → LH/FSH → testosterone/estrogen deficiency; most common organic cause of secondary hypogonadism in both sexes; causes anhedonia and desire suppression independently
MRI to exclude pituitary adenoma; dopamine agonist (cabergoline/bromocriptine) if prolactinoma confirmed; correct underlying cause (medications, thyroid)
Melanocortin agonism ineffective in significant hyperprolactinemia — dopaminergic tone suppression blunts the MC/dopamine desire circuit. Normalize prolactin first
Hypothyroidism (elevated TSH)
Thyroid deficiency is one of the most common, underdiagnosed causes of low libido, fatigue, and anorgasmia in both sexes; also blunts GH-axis response (relevant to metabolic hub peptides)
Levothyroxine titration to TSH 1.0–2.0 mIU/L; consider T3/T4 combination in refractory cases
Thyroid normalization alone frequently resolves desire complaints. Rescreen for HSDD after 3 months of euthyroid status before adding peptide
Low Total Testosterone (men)
Primary or secondary hypogonadism; the most common male endocrine contributor to low desire and erectile dysfunction; often coexists with metabolic syndrome
TRT (IM testosterone, transdermal, subcutaneous pellets) per clinical guideline; address contributing factors (obesity, medications, sleep apnea)
PT-141 off-label ED use is most appropriate after testosterone optimization; it addresses central (psychogenic/neurogenic) components not remedied by testosterone alone
PT-141 — Prescribing Reference
PT-141 (Vyleesi®) FDA-Label Prescribing Protocol
As the FDA-approved compound in this hub, PT-141 (bremelanotide) carries the most complete prescribing framework. The following protocol is derived from the FDA-approved label (NDA 210557), the RECONNECT Phase III trial publications, and post-marketing prescribing experience. Off-label use in men or post-menopausal women requires adaptation of this framework with explicit informed consent about the off-label nature.
Approved Indication
HSDD — Premenopausal Women
FDA NDA 210557 (June 21, 2019). Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women with distress. Diagnosis requires patient-reported distress (FSDS score) — desire reduction without distress does not meet diagnostic threshold.
Approved Dose & Route
1.75 mg SC, On-Demand
Single-use auto-injector (Vyleesi®), subcutaneous injection into abdomen or thigh, administered approximately 45 minutes before anticipated sexual activity. Maximum 1 dose per 24 hours; no more than 1 dose per planned sexual activity event. Not a daily medication.
Onset / Duration
45 min onset · ~8 hr window
Tmax ~1 hour for bremelanotide. Desire-enhancing effects begin ~45 minutes post-injection. BP effect (transient systolic increase) peaks at approximately 12 hours post-dose — not at Tmax. The clinical desire window is approximately 8 hours; BP monitoring recommendation extends to 12 hours.
Nausea Management
40% Incidence — Addressable
Nausea was the most common adverse effect in Phase III (40.1% PT-141 vs. 12.2% placebo). Ondansetron (4–8 mg ODT) taken 30 minutes before the PT-141 injection is a standard co-prescription strategy that substantially reduces nausea incidence. Nausea typically resolves within 2–4 hours. Dose should not be taken with a large meal immediately prior.
Blood Pressure Protocol
Transient +6 mmHg Systolic
Phase III data: average systolic BP increase +5.6 mmHg peaking approximately 12 hours post-dose, self-resolving by 24 hours. Baseline BP measurement required before initiating therapy. Patients with BP >140/90 at baseline should be evaluated and treated before PT-141 initiation. Monitor BP at 12 hours after first dose if patient has any cardiovascular risk factors.
Contraindications (FDA Label)
CV Disease / PDE5 Inhibitors
Absolute: known cardiovascular disease (history of CAD, CHF, CVA, hypertensive crisis). Do not use within 24 hours of PDE5 inhibitors (sildenafil, tadalafil, vardenafil) — additive BP reduction risk with vasodilatory effects. Known hypersensitivity to bremelanotide or excipients. Pregnancy — teratogenicity data insufficient.
Limitation of Use
Not for Post-Menopause (Label)
FDA label specifies premenopausal women as the approved population. Post-menopausal use is off-label — requires explicit informed consent. Additionally: not for use to enhance sexual performance in women without HSDD diagnosis; not a treatment for relationship or communication issues; not for use in men (off-label, Phase II data only).
Follow-Up Assessment
8-Week Response Check
Formal FSFI desire domain and FSDS reassessment at 8 weeks of on-demand use. If patient reports 3+ satisfying sexual events per month improvement (the Phase III primary endpoint) with acceptable tolerability, continue; if no subjective benefit with good tolerability after 8 weeks, reassess diagnosis and consider discontinuation.
Focal Hyperpigmentation — Label Warning
PT-141 may cause focal hyperpigmentation of the face, breasts, and gums — particularly in patients with darker skin tones. This occurs via residual MC1R activation. Unlike Melanotan II, PT-141's hyperpigmentation risk is characterized, disclosed in the FDA label, and generally mild/reversible. Patients should be counseled about this cosmetic effect before initiation. Patients who develop significant hyperpigmentation may require dose interruption.
Library — Sexual Health Research Compounds
Compound Evidence Summary
Four compounds address the melanocortin and kisspeptin axes with varying degrees of clinical evidence. The evidence gap in this library is wide: PT-141 (Level I, FDA-approved Phase III RCT) sits alongside Melanotan II (Level V, no human RCT data, not FDA-approved). Evidence tier is the first — and most important — differentiator.
The only FDA-approved on-demand treatment for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. A cyclic heptapeptide derived from Melanotan II with selective central CNS activity. Acts via MC3R/MC4R in hypothalamic desire circuits — distinct from hormonal or peripheral vasoactive mechanisms. FDA NDA 210557, approved June 21, 2019. Phase III: RECONNECT trials (Simon 2018, n=627). Self-administered SC injection 45 minutes before anticipated sexual activity; not a hormone; no systemic testosterone or estrogen effects.
The master regulator of GnRH pulsatility, kisspeptin is the endogenous neuropeptide that gates hypothalamic GnRH release and, by extension, the entire reproductive hormone axis (LH, FSH, testosterone, estrogen). Kisspeptin deficiency underlies hypothalamic amenorrhea and some forms of hypogonadotrophic hypogonadism. Research peptides (Kp-10, Kp-54) have shown promise in Phase II trials for ovulation induction in IVF (Abbara 2015) and restoration of reproductive axis pulsatility in functional hypothalamic amenorrhea. No FDA approval; regulatory status is unresolved — an earlier "Category 2" safety-concern nomination was withdrawn in April 2026, but that does not grant compounding eligibility, and kisspeptin was not among the peptides addressed by the FDA's July 2026 Pharmacy Compounding Advisory Committee vote. Investigational use only.
A 9-amino acid hypothalamic neuropeptide with FDA approval for IV obstetric use (labor induction/augmentation) only — not for any sexual-wellness indication. Intranasal oxytocin is used off-label for sexual bonding enhancement, orgasm facilitation, and social connectedness. The mechanistic basis is real: endogenous oxytocin surges during orgasm are well-documented, and OXTR signaling in the nucleus accumbens mediates pair-bonding. But the intranasal-oxytocin literature is in the middle of a 2025-2026 replication crisis — including a null pre-registered report and OXTR-expression-contingent effects — and off-label data for sexual function endpoints specifically is small, mixed, and not definitive. Clinical use requires explicit off-label informed consent.
⚠ Not recommended — linked to melanoma case reports and a Skin Cancer Foundation warning; see why we steer clear of it. The pharmacological predecessor to PT-141. Melanotan II is a non-selective melanocortin receptor agonist developed in the 1980s as a tanning peptide before its pro-erectile effects were discovered. PT-141 (bremelanotide) is a cyclic, modified descendant engineered for CNS selectivity without the tanning side effect. Melanotan II lacks the MC4R selectivity of PT-141, activating MC1R (tanning), MC5R (exocrine glands), and other receptors that produce nausea, flushing, yawning, and spontaneous erections. Not FDA-approved; not a research chemical with IND status; no Phase II/III trials. Use carries unknown purity/quality risks from unregulated supply.
⚠ Not RecommendedMelanoma Case ReportsNot FDA-ApprovedNon-Selective MC1-5RUnregulated Supply
The Sexual Health library spans the widest evidence gap of any PeptideReport.ai hub — from the FDA-approved PT-141 (Level I, Phase III RCT, n=627) to Melanotan II (Level V, no human RCT, unregulated compound). This table establishes the clinical evidence context for each compound and is the starting point for any prescribing consideration.
Compound
Mechanism
Evidence Level
Best Human Data
Regulatory Status
Clinical Role
PT-141 (Bremelanotide)
MC3R/MC4R agonist; central CNS desire circuit activation via PVN oxytocin and limbic dopamine pathways
I — Phase III RCT
Simon 2018 RECONNECT trial, n=627; Kingsberg 2019; pre-specified endpoints: SSEs/month, desire score, distress score — all statistically significant vs. placebo
Abbara 2015 (Vigo 2015, 2016) — Phase II IVF ovulation induction; Jayasena 2014 — Kp-54 in healthy men; Horikoshi 2003 — receptor characterization; no Phase III RCT
No FDA approval; not commercially available; Phase II investigational status; compounding pharmacy source for off-label research use
Hypothalamic amenorrhea (restoration of GnRH pulsatility); IVF research (ovulation trigger alternative to hCG); male hypogonadotrophic hypogonadism research
Intranasal OT for orgasm: Behnia 2014 (n=29, male); Burri 2008 (n=31); mixed results across sexual function endpoints; larger meta-analyses show modest/inconsistent effects
IV oxytocin FDA-approved (Pitocin®) for obstetric use only; intranasal off-label; compounding pharmacy; OTC oxytocin nasal spray sold as supplement (no FDA oversight of intranasal route)
Off-label orgasm enhancement, bonding, social anxiety; requires explicit off-label consent; evidence quality insufficient for formal prescribing guidelines
Melanotan II
Non-selective MC1R/MC3R/MC4R/MC5R agonist; broad melanocortin receptor activation including tanning (MC1R) and exocrine (MC5R) pathways not targeted clinically
V — Preclinical
Animal data: spontaneous erection in rats, increased mounting behavior; Wessells 1998 (n=10, intracavernosal, not SC); no SC Phase II/III human data; Melanotan II itself was never advanced to Phase II as a named compound
No FDA approval; no IND filing; no regulatory status; sold as "research chemical" from unregulated supply chains with no manufacturing standards or purity verification
Not recommended for clinical use; included here as historical/mechanistic predecessor to PT-141; practitioners encountering patient use should counsel on risk profile and pivot to FDA-approved PT-141
FDA Approval in Context — June 21, 2019
PT-141's 2019 FDA approval (Vyleesi®, NDA 210557) represents a landmark: it is the first and only CNS-acting melanocortin agonist approved for a sexual function indication, and only the second FDA-approved treatment specifically for female sexual dysfunction (after flibanserin/Addyi in 2015, which has a different mechanism and a daily-use requirement). The FDA's approval was based on pre-specified, patient-reported outcomes — satisfying sexual events (SSEs) per month, the Female Sexual Function Index desire domain, and the Female Sexual Distress Scale — not physician-rated endpoints. This patient-centered evidence framework distinguishes PT-141's approval from older pharmaceutical precedents in the sexual health space.
Clinical Decision Tool
Patient Phenotype → Compound Selection
Sexual health complaints are heterogeneous. Desire disorders, arousal disorders, orgasm disorders, and reproductive axis dysfunction each map to different mechanisms and, therefore, different compounds. This framework links presenting clinical phenotype to the evidence-based compound selection logic for this library.
Phenotype 1
Low Desire / HSDD Premenopausal Woman
Reduced sexual desire causing personal distress; not explained by relationship factors, medication side effects, or hormone deficiency; endogenous hormones (testosterone, estrogen) within normal range. Screened using the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS).
→ PT-141 (Vyleesi®) · FDA-Approved First Line
Phenotype 2
Hypothalamic Amenorrhea / Anovulation
Secondary amenorrhea with low FSH/LH, normal prolactin, no pituitary lesion — functional GnRH pulse suppression (energy deficit, exercise, stress). Kisspeptin axis suppressed as the primary mechanism. GnRH analogue therapy is the first-line; kisspeptin is an investigational alternative for research contexts.
→ Kisspeptin-54 · Investigational (Phase II)
Phenotype 3
Orgasmic Dysfunction / Anorgasmia
Difficulty achieving orgasm or reduced orgasmic intensity; SSRI-induced anorgasmia is a common iatrogenic presentation; post-menopausal changes in orgasmic response. Oxytocin's endogenous role in the orgasmic reflex makes it mechanistically plausible; small RCT data is mixed. Off-label informed consent required.
Psychogenic or mixed neurogenic ED not responding to PDE5 inhibitors; loss of morning erections or context-specific failure suggesting central contribution vs. pure vascular ED. MC4R agonism in the PVN drives central pro-erectile signaling. PT-141 has Phase II data in men (off-label). Not a substitute for PDE5i evaluation.
→ PT-141 · Off-Label in Men (Phase II Data Only)
Phenotype 5
Patient Self-Reporting Melanotan II Use
Patient presents having self-administered Melanotan II from unregulated source. Counsel on: non-selective receptor profile vs. PT-141; unverified purity and sterility; no human Phase II/III safety data; spontaneous erection, nausea, flushing, hyperpigmentation risks. Transition conversation to FDA-approved PT-141 for the same primary indication.
→ Counsel + Transition to PT-141 (FDA-Approved)
Phenotype 6
Post-Menopausal Low Desire (Hormones Optimized)
Post-menopausal woman with desire disorder despite optimized hormone therapy (estradiol + testosterone). Hormones addressed — residual central desire circuit suppression may respond to melanocortin agonism. PT-141's approved indication is premenopausal; post-menopausal use is off-label. Phase III data did not exclude post-menopausal women from safety analysis but efficacy was not powered for this subgroup.
Safety profiles in this library are stratified by evidence quality — PT-141's Phase III safety database is the gold standard; other compounds have substantially less characterized safety profiles. The most important safety principle for off-label compounds: the absence of documented harm does not equal established safety.
PT-141 · Level I
Nausea (40%), Flushing (20%), BP Transient ↑
Primary adverse effects in Phase III: nausea (40.1% vs. 12.2% placebo), flushing (20.2%), injection site reactions, transient BP increase (average +6 mmHg systolic, peaks at ~12 hours post-dose). Nausea is the dose-limiting adverse effect — ondansetron co-prescription is often used. No use within 24 hours of PDE5 inhibitors. Not for use with antihypertensives unless BP monitored. FDA label contraindications: cardiovascular disease, known hypersensitivity.
Kisspeptin · Level IIb
Generally Well-Tolerated in Phase I/II
Phase I/II kisspeptin studies (IV and SC) reported minimal adverse effects — mild injection site reactions, no significant cardiovascular or neuroendocrine adverse events. The primary clinical concern is over-stimulation of the LH surge in IVF context (ovarian hyperstimulation syndrome risk, managed with dose titration). Long-term safety of chronic kisspeptin administration in humans is not characterized. GnRH excess risk theoretical with sustained high-dose use.
Oxytocin Intranasal · Level IIb
Headache, Nasal Irritation, Anxiety (Paradoxical)
Intranasal OT generally well-tolerated in small RCTs. Known adverse effects: headache, nasal irritation, mild nausea. Paradoxical anxiety/distress has been reported in some subjects — OTR agonism in the amygdala can enhance social salience, which in some individuals manifests as anxiety rather than bonding. IV oxytocin (obstetric use) carries uterotonic cardiovascular risks not relevant to intranasal low-dose. No long-term intranasal safety studies.
Non-selective MC1-5R agonism produces predictable off-target effects: significant nausea/vomiting, facial flushing, yawning, spontaneous erections (sometimes unwanted). MC1R activation causes hyperpigmentation including pre-existing nevi enlargement — rare melanoma cases temporally associated with MT-II use in case reports (causation not established, but concerning given the biology). Unregulated supply: no sterility, purity, or concentration verification. Physicians encountering patient use should advise cessation and FDA-approved alternative.
Melanotan II — Nevi Enlargement and Melanoma Concern
MC1R stimulation by Melanotan II activates the melanogenesis pathway in melanocytes — the same signaling that drives UV-induced tanning and, in dysregulated form, melanoma. Multiple case reports have documented rapid enlargement of pre-existing nevi during Melanotan II use, and at least several temporal associations with melanoma diagnosis have been reported in the literature (Curnow 2009; Dawber 2004). No causal relationship has been definitively established, but the mechanistic plausibility is high. Patients with a personal or family history of melanoma, multiple atypical nevi, or Fitzpatrick skin type I should be specifically counseled against Melanotan II use. The absence of this warning on the FDA-approved PT-141 (Vyleesi®) label reflects the superior MC4R selectivity of PT-141 vs. MT-II's non-selective profile.
Frequently Asked Questions
Sexual Health Peptide Hub — FAQ
Common questions about the compounds, evidence levels, and safety framing covered across this hub.
What sexual-health peptides does PeptideReport.ai cover in this hub?
This hub profiles four compounds that act on the two central axes governing sexual function: the melanocortin system and the kisspeptin/GnRH axis. They are PT-141 (bremelanotide/Vyleesi®), Kisspeptin, Oxytocin, and Melanotan II. Evidence quality varies widely across these four — from the FDA-approved PT-141 (Level I) to the preclinical, not-recommended Melanotan II (Level V).
Is PT-141 (Vyleesi®) FDA-approved?
Yes. PT-141 (bremelanotide) is FDA-approved under NDA 210557 (June 21, 2019) as Vyleesi®, an on-demand treatment for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. It is the only FDA-approved compound in this hub and carries Level I evidence from the Phase III RECONNECT trials (n=627). Use in men or in post-menopausal women is off-label, per the FDA label's Limitation of Use.
Why does PeptideReport.ai flag Melanotan II as not recommended when it's covered in the same hub as PT-141?
Melanotan II is included here as the mechanistic predecessor to PT-141, not as a comparable clinical option. Unlike PT-141's selective MC3R/MC4R action, Melanotan II non-selectively activates all five melanocortin receptors, producing tanning, nevi enlargement, and case reports of melanoma association — carrying Level V (preclinical only) evidence with no FDA approval, no IND filing, and unregulated supply-chain risk. This hub explicitly does not recommend Melanotan II and counsels patients using it to discuss transitioning to the FDA-approved PT-141 with their physician.
What is the evidence for Kisspeptin in this category?
Kisspeptin carries Level IIb evidence — Phase I/II human data, not Phase III. Research peptides (Kp-10, Kp-54) have shown promise for ovulation induction in IVF and for restoring GnRH pulsatility in hypothalamic amenorrhea, but no FDA-approved KISS1R agonist exists and its regulatory status is unresolved. It is discussed here strictly as an investigational compound for reproductive-axis research contexts.
What is the evidence for Oxytocin's role in sexual health?
Oxytocin (Pitocin®) is FDA-approved only for IV obstetric use; intranasal use for orgasm facilitation or bonding is off-label and carries Level IIb evidence from small, mixed-result RCTs. This hub notes that literature is in the middle of an ongoing 2025–2026 replication crisis, so any off-label use requires explicit informed consent and should not be framed as an established therapy.
What are the biggest safety considerations across this category?
Safety data quality tracks evidence tier: PT-141 has a well-characterized Phase III safety database (nausea, transient blood pressure increase, contraindication with PDE5 inhibitors and cardiovascular disease), while Kisspeptin and Oxytocin have only small-study safety signals and no long-term human data. Melanotan II is the outlier — its non-selective receptor activation and unregulated sourcing carry the highest documented risk profile, including melanoma-association case reports, which is why this hub does not recommend it and treats hormonal optimization as a required prerequisite before considering any peptide in this category.
About the Author
Dr. Scott DelBoccio, DMD
Physician-Researcher · PeptideReport.ai · Founder
Dr. Scott DelBoccio, DMD, is the founder and physician-researcher behind PeptideReport.ai. His work focuses on synthesizing emerging peptide research literature into E-E-A-T–compliant clinical education for healthcare practitioners. All hub and compound profiles at PeptideReport.ai are physician-authored, evidence-graded, and designed to meet the evidentiary standards appropriate for YMYL health content. Research profiles do not constitute medical advice and are intended for educational and informational purposes only.
Research Resource Disclaimer. This Sexual Health Research Hub is authored by Dr. Scott DelBoccio, DMD, and is intended for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. PT-141 (Vyleesi®) is an FDA-approved prescription medication for HSDD in premenopausal women; all other compounds described have off-label or investigational status only. Sexual health treatment decisions — including compound selection, dosing, and monitoring — must be made by a licensed prescribing physician with full knowledge of the patient's medical and psychological history. This hub does not recommend or endorse the use of any compound outside its FDA-approved indication.